Subnets / SN68
NOVA SN68
NOVA (subnet 68) is a Bittensor subnet held by 4,246 unique coldkeys. Its liquidity pool holds 44.7k τ, with the alpha token trading at 0.0220 τ. Roughly 54% of tracked holders are in profit. Over the last 7 days the alpha price is down 3.7% in TAO terms. Full insider flow, whale tracking and the complete proprietary factor set for NOVA are available to SubnetStats subscribers.
ALPHA PRICE
0.0220 τ
IN TAO
HOLDERS
4,246
UNIQUE COLDKEYS
POOL DEPTH
44.7k τ
TAO IN POOL
7D MOMENTUM
-3.7%
ALPHA vs TAO
Project activity
It’s only a matter of time before it becomes obvious to everyone that drug discovery is the best and potentially most rewarding use of compute and capital ↓
By then, we will have an unstoppable, increasingly automated system of incentive mechanisms connected with experimental va
New NOVA Blueprint winner
Delivers 7.02× PSICHIC inference speedup
from 214 → 1,502 protein–ligand pairs/sec
on an RTX 3090
That means the same inference workload can be completed with ~86% less time and compute costs, allowing substantially more chemical space to be evaluated
Build the next winning search algorithm:
Boltz-2 is coming to NOVA Blueprint.
The integration is now available for testing.
With this release, Boltz-2 scoring moves to a dedicated GPU oracle rather than running inside the miner sandbox. Competitors can query the oracle through
Mounjaro and Zepbound were 56% of @EliLillyandCo's 2025 revenue. @definiumtx's LSD tablet just got a 2nd FDA Breakthrough designation, this one for depression.
Both improve self-regulation, which can impact health, relationships, work and longevity.
Agency Therapeutics 🧵
The distance between intention and action is treated as a question of discipline.
GLP-1s, stimulants, psychedelics act on the biology of self-regulation.
Agency Therapeutics may be medicine's next major category.
Read: thesis, pharmacology, and how we're designing them ↓ https
https://t.co/bDVPWPA2vJ
NOVA Blueprint: Better Search Meets Better Models
Transitioning to Boltz-2-based scoring this week.
This matters because Boltz-2 gives Blueprint a richer scoring layer than PSICHIC. Boltz-2 is a structural biology foundation model that predicts biomolecular structure and bindin
Optimizing Discovery Through Adaptive Incentives
We track winning submissions and network-wide trends to generate the diversity and signal needed downstream.
We continuously tune parameters to guide the network through ultra-large chemical and biological spaces, producing rich
NOVA is a global market for virtual drug discovery: the first decentralized platform to coordinate continuous competitions to identify novel therapeutics and advance discovery tools.
3 competitions run in parallel across small molecules, nanobodies, and chemical search algorithm
NOVA targets keep getting more interesting
HDACs have been developed mainly as cancer targets. Studies published in 2026 point to a broader opportunity: selectively modulating the epigenetic machine that helps determine how the brain learns, adapts, and recovers.
A few findings
History in the making.
Huge congratulations to the teams at @moderna_tx and @Merck their individualized mRNA cancer therapy, which just became the first of its kind to succeed in a Phase 3 trial—meeting both recurrence-free survival and distant metastasis-free survival endpoints
NOVA Compound - more drug-like submissions
We’re adding the BRENK structural filter to our molecule validity criteria. The filter identifies and removes chemical structures associated with undesirable properties in drug development.
This further constrains the search beyond pre
NOVA Compound - 20x more molecules
As miner performance improved, Boltz-2 inference became one of the primary bottlenecks limiting how many molecules each miner could be evaluated on. We've reworked our inference parallelization strategy to support up to 20× more molecule evalua
NOVA Blueprint update
The next Blueprint winner will receive 30,000 $NOVA (~$144,000 USD).
For context, that's nearly 3× the recent #BELKA drug discovery competition and larger than @AnthropicAI one time Life Sciences hackathon.
We've intentionally set a very high bar for re
https://t.co/8l4tCywJ61
NOVA Blueprint Registration Update
Blueprint miners will no longer need a registered UID on subnet 68 to compete. Blueprint will instead use its own registration system.
• 10 alpha per entry
• 64 registration slots per day
• Credits held at the coldkey level
• Any hotkey tied t
NOVA Nanobodies: Experimental validation
We're excited by the quality of submissions we've received in our nanobodies competition and are pleased to announce that we’re beginning nanobody production in partnership with @Yalotein.
This marks the start of experimental validation
https://t.co/1fuleBo3iH
We're hosting a global virtual hackathon everyday!
NOVA is the world's largest continuous AI competition for drug discovery.
Current rewards:
- $4k/day for Small Molecule Screening
- $6k/day for Nanobody Design
- $37K (+$4k/day) for Chemical Search Algorithms
Calling all ML en
The new https://t.co/l3s3hIg7ds is now live.
Take a deeper look at:
• Our approach to AI drug discovery
• NOVA's competition architecture
• How value is created across the platform
• Partnership opportunities
Thank you to @14islands for bringing the redesign to life. https://t.
Incentive Alignment Update: Miner burn 0%
Our goal is to leverage #Bittensor to drive innovation. As subnet owners, we also have a responsibility to manage token health.
This is why we—along with several other leading subnets—have historically burned a portion of miner emission
Geopolitical conservatism in biotech risks becoming anti-progress.
Biosecurity matters but scientific talent is globally distributed and the tools for discovery should be too.
@metanova_labs mission is more important than ever.
Decentralized, permissionless infrastructure isn
NOVA Blueprint Update: The Triple Crown
We’re improving the blueprint’s winner selection mechanism to better reward strong, generalizable performance.
Previously, a challenger could replace the current king by clearing the winning threshold in a single epoch. Under the new **
Decentralized AI isn't just philosophically better, it's functionally necessary for science to move at the speed required.
Anthropic already made Claude structurally useless for serious biotech work before any government pressure.
When they launched Claude Opus 4, they activate
NOVA Conviction Update + Incentive Alignment
We didn't choose drug discovery because it was an easy or fast problem to solve. We chose it because it's one of the hardest and most meaningful problems AI can tackle. Our ambition and track record reflects our commitment to long-ter
SELLERS DRAINED
68%
28D SELLERS EMPTIED OUT
CAPITULATION
-1.28
BOUNCE COMPOSITE (z)
HEAT 7D
0.13×
VOLUME ÷ POOL DEPTH
HOLDERS IN PROFIT
54%
TRACKED WALLETS · ENTRY BELOW PRICE
See who's buying and selling NOVA — every trade classified miner / validator / owner / outsider, plus holder cost basis and the full 23-factor screener.
OPEN THE INSIDER TAPE →